Neuroscience

Paradigm Health Raises $78 Million Series B to Make Clinical Trials Part of Routine Care Across the U.S. and Globally

COLUMBUS, Ohio and NEW YORK, Dec. 4, 2025 /PRNewswire/ -- Paradigm Health, the technology company rebuilding the clinical research ecosystem,...

Neurophet Appoints Josh Cohen, Former Executive from a Global Medical AI firm, as Head of Americas Business — To Accelerate U.S. Market

Expert in sales and commercial strategy…Ex-Philips and previously served as Chief Commercial Officer (CCO) at Cortechs.aiTo strengthen revenue growth of...

Palisade Bio Strengthens Clinical Leadership Team with Appointment of James Izanec, MD, AGAF as Vice President, Clinical Development

Veteran gastroenterologist and clinical development leader with deep expertise driving global Phase 2/3 programs across immunology, neurology, and gastrointestinal disease...

SoluPet Inc. (SoluPet) Announces Strategic Partnership With CHC Healthcare Group (CHC) to Advance Canine Cognitive Health in Asia

Partnership with CHC in Taiwan will pilot SoluPet's flagship Neuronal Defense™ formulation through CHC's veterinary and consumer-health ecosystem TORONTO, ON...

INmune Bio Reports New Phase 2 Grey Matter Imaging Data at CTAD Conference Reinforcing XPro1595’s Evidence Base in High-Inflammation Alzheimer’s Patients

Boca Raton, FL, Dec. 01, 2025 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB), a clinical-stage biotechnology company developing inflammation...

SKYRIZI® (risankizumab) Receives Positive Reimbursement Recommendation by Canada’s Drug Agency for Ulcerative Colitis and AbbVie Concludes Letter of Intent with the pan-Canadian Pharmaceutical Alliance

SKYRIZI® (risankizumab), an IL-23 inhibitor, received two consecutive positive reimbursement recommendations by Canada’s Drug Agency (CDA-AMC) for inflammatory bowel diseases,...

Anavex Life Sciences to Present Oral Blarcamesine Data at the 18th Clinical Trials on Alzheimer’s Disease (CTAD) Conference

One Oral Late Breaking Communication and Two Poster PresentationsNEW YORK, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp....

Teva receives European Commission approvals for PONLIMSI® (denosumab) Biosimilar to Prolia® and DEGEVMA® (denosumab) Biosimilar to Xgeva®

Following the positive opinions of the Committee for Medicinal Products for Human Use (CHMP), the European Commission has granted marketing...

error: Content is protected !!